Imetelstat (telomerase inhibitor for MPN)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-17 — A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment: IMpactMF (Phase III, trial-late): randomized comparison of imetelstat (telomerase inhibitor) vs best available therapy in intermediate-2/high-risk myelofibrosis relapsed/refractory to JAK inhibitors, with overall survival as the primary endpoint — first Phase III OS readout for a telomerase-targeting agent in the JAKi-refractory MF salvage setting. (novelty: 4)
Open questions
Related
Contributing findings
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
17-jun-2026
novelty 4
per-area 4
introduces